We are live on ! Find out more

Invivyd

IVVD

Market cap $188M

0.6393 USD

+0.0027

0.42%

At close Updated Oct 21, 4:00 PM EDT

Pre-market

After hours

0.6580

+0.0187

2.93%

1 day

0.42%

5 days

3.28%

1 month

-37.32%

3 months

-6.22%

6 months

-59.79%

Year to date

-74.43%

1 year

-68.66%

5 years

-98.1%

10 years

-96.94%

About: Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.

Employees: 122

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 26.7%

Neutral 66.7%

Negative 6.7%

Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026

VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd VMS063 demonstrated potent in vitro antiviral activity against contemporary measles virus variants, and attractive biophysical properties supporting its potential utility for both treatment and prevention of measles Invivyd is scaling up production toward clinical development in 2027 There are currently no FDA approved treatments for measles, leaving a major gap in the public health and medical management of measles The U.S. is experiencing a record-breaking number of measles cases in 2026, and a significant immunity gap has emerged, leaving millions of Americans vulnerable to measles infection and associated complications NEW HAVEN, Conn., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the presentation of preclinical data describing its novel, potential first- and best-in-class investigational monoclonal antibody candidate VMS063 at IDWeek 2026™ in Washington, D.C.

Invivyd Presents VMS063, a Potential Best-in-Class Monoclonal Antibody Candidate for the Treatment and Prevention of Measles, at IDWeek 2026

Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome

NEW HAVEN, Conn., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) and the SPEAR Study Group today announced the initiation of FLINTLOCK, a Phase 2 clinical trial evaluating the safety, tolerability, pharmacokinetics, and clinical efficacy of high-dose monoclonal antibody VYD2311 in individuals with Long COVID or Post-Vaccination Syndrome (PVS), also known as COVID vaccine injury.

Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW HAVEN, Conn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that on October 1, 2026, Invivyd granted six newly hired non-executive employees options to purchase an aggregate of 157,500 shares of its common stock, each as a material inducement for each employee's entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan.

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Invivyd's VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval

Invivyd NASDAQ: IVVD reported topline results from its Phase III LIBERTY study of VYD2311, an investigational low-dose intramuscular monoclonal antibody designed to prevent COVID-19, and outlined plans to pursue an accelerated-approval pathway with the U.S. Food and Drug Administration.

Invivyd's VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval

Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody

Invivyd Inc. (NASDAQ:IVVD) on Tuesday announced topline results from its Phase 3 LIBERTY study of its investigational COVID-19 monoclonal antibody candidate.

Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody

Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission Transcript

Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission Transcript

Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission Transcript

Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311

NEW HAVEN, Conn., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced positive, clinically meaningful, and statistically significant topline data from the LIBERTY Phase 3, randomized, double-blind, active controlled study evaluating the safety and tolerability of (1) VYD2311, Invivyd's investigational COVID-directed monoclonal antibody candidate, (2) mRNA-based COVID-19 vaccine COMIRNATY® (mRNA-based COVID-19 vaccine, COVID-19 mRNA vaccine, or COVID vaccine), and (3) VYD2311 co-administered with mRNA-based COVID-19 vaccine. The study also evaluated the potential for immunologic interference between VYD2311 and mRNA-based COVID-19 vaccine. LIBERTY is a companion study to DECLARATION, the ongoing placebo-controlled pivotal study of VYD2311 for pre-exposure prophylaxis of symptomatic COVID-19.

Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311

These beaten-down stocks could bounce back in January, if history is any guide

Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year

These beaten-down stocks could bounce back in January, if history is any guide

3 Small-Cap Biotechs With Binary Catalysts on the Calendar

For small-cap biotech investors, a single date on the calendar can matter more than a quarter's worth of earnings reports. These companies often burn cash for years without product revenue, betting everything on a single clinical trial readout or an FDA decision.

3 Small-Cap Biotechs With Binary Catalysts on the Calendar

Invivyd to Participate in Upcoming September Investor Conferences

NEW HAVEN, Conn., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that Marc W. Elia, Chairman and Chief Executive Officer, and members of company management will participate in three upcoming investor conferences:

Invivyd to Participate in Upcoming September Investor Conferences

See News Rankings

Price charts implemented using Lightweight Charts™